Opinion

Video

Clinical Data on Finerenone in Diabetic Kidney Disease

Author(s):

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.

Related Videos
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Psoriasis podcast
Related Content
Dhruv Kazi, MD | Credit: PCSK9 Forum
November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 2nd 2024

FDA Committee Casts Negative Vote on Sotagliflozin in Type 1 Diabetes

Patrick Campbell
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
10-Year Follow-Up Shows Lasting Benefits of Bariatric Surgery for Teens with Severe Obesity
October 30th 2024

10-Year Follow-Up Shows Lasting Benefits of Bariatric Surgery for Teens with Severe Obesity

Chelsie Derman
Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center
October 21st 2024

Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.